← Human Trials & Peer-Reviewed Studies
Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial
Plain-language guide to PMID 38985162 (2024): double-blind randomized controlled trial study of Semaglutide.
Key Facts
- PMID
- 38985162
- Journal
- Diabetologia
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Wang W et al. (10 authors)
- DOI
- 10.1007/s00125-024-06142-3
What This Study Did, in Plain Language
What Was Tested
Researchers studied Semaglutide in this randomized controlled trial publication.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
The Peptide Innovation for Early Diabetes Treatment (PIONEER) 11 trial was a double-blind, randomised, Phase IIIa trial conducted across 52 sites in the China region (mainland China and Taiwan), Hungary, Serbia and Ukraine.
Randomisation was stratified according to whether participants were from the China region or elsewhere.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.
The primary and confirmatory secondary endpoints were change from baseline to week 26 in HbA1c and body weight (kg), respectively.
What Was Measured
PubMed files the paper under topics including Blood Glucose, China, Diabetes Mellitus, Type 2, East Asian People, Glucagon-Like Peptides, Glycated Hemoglobin and Hypoglycemic Agents.
Author keywords: GLP-1 analogue, Glycaemic control, Incretin therapy, Phase III, Semaglutide and Type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.
The abstract goes on to report its results in about 14 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2024 (Diabetologia), a journal based in Germany.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.